Xencor Inc (Xencor) is a clinical-stage biopharmaceutical company that discovers and develops engineered monoclonal antibodies and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company product pipeline includes Vudalimab (PD1 x CTLA4), Plamotamab (CD20 x CD3), XmAb819 (ENPP3 x CD3), XmAb564 (IL-2-Fc) and XmAb104 (PD1 x ICOS). Its other pipeline includes XmAb306/RO7310729, XmAb968 and XmAb662 (IL12-Fc), among others. Xencor's Vudalimab is a bispecific antibody that simultaneously targets immune checkpoint receptors PD-1 and CTLA-4 and is designed to promote tumor-selective T-cell activation. Xencor is headquartered in Monrovia, California, the US.
Xencor Inc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Products Pipeline: | XmAb |
Vudalimab (PD1 x CTLA4) - Metastatic Castration-Resistant Prostate Cancer, Advanced Gynecologic and Genitourinary Malignancies | |
Plamotamab (CD20 x CD3) - B-Cell Tumors | |
XYZ | |
XYZ | |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Contracts/Agreements | In February, the company entered into an agreement with Atreca to develop T cell engaging bispecific antibody directed against novel solid tumor target. |
2023 | Contracts/Agreements | In January, the company and Caris Life Sciences announced an expansion of their collaboration to research, develop and commercialize novel XmAb bispecific and multi-specific antibodies directed against novel targets. |
2021 | Contracts/Agreements | In October, the company and Janssen Biotech entered into an agreement for the development and commercialization of plamotamab and XmAb CD28 bispecific antibody combinations to treat patients with B-cell malignancies. |
Competitor Comparison
Key Parameters | Xencor Inc | Pfizer Inc | AbbVie Inc | AstraZeneca Plc | Bristol-Myers Squibb Co |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United Kingdom | United States of America |
City | Pasadena | New York | North Chicago | Cambridge | Princeton |
State/Province | California | New York | Illinois | England | New Jersey |
No. of Employees | 280 | 88,000 | 50,000 | 89,900 | 34,100 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Bassil I Dahiyat | Director; Chief Executive Officer; President | Executive Board | 2005 | 52 |
Bart Cornelissen | Chief Financial Officer; Senior Vice President | Senior Management | - | - |
Allen Yang, Ph.D., MD | Senior Vice President; Chief Medical Officer | Senior Management | 2019 | 55 |
John R Desjarlais | Senior Vice President - Research; Chief Scientific Officer | Senior Management | 2014 | 58 |
Celia Eckert | Senior Vice President; Secretary; General Counsel | Senior Management | 2019 | 51 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer